{"id":"gen-xp13512","safety":{"commonSideEffects":[{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Somnolence"},{"rate":null,"effect":"Peripheral edema"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL6068607","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"XP13512 is designed to overcome the saturable absorption of gabapentin by leveraging the large neutral amino acid transporter type 1 (LAT1) for active transport across the intestinal epithelium. This transporter-mediated mechanism allows for improved oral bioavailability and more consistent plasma levels compared to gabapentin alone, potentially enabling lower doses or improved efficacy in neuropathic pain conditions.","oneSentence":"XP13512 is a prodrug of gabapentin that uses a novel amino acid transporter-mediated delivery system to enhance absorption and bioavailability in the gastrointestinal tract.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:47:21.028Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Postherpetic neuralgia"},{"name":"Diabetic peripheral neuropathy"}]},"trialDetails":[{"nctId":"NCT01668667","phase":"PHASE4","title":"Gabapentin Enacarbil (GSK1838262) Adult Restless Leg Syndrome (RLS) Post Marketing Commitment Study","status":"COMPLETED","sponsor":"XenoPort, Inc.","startDate":"2012-06","conditions":"Restless Legs Syndrome","enrollment":501},{"nctId":"NCT01332318","phase":"PHASE2","title":"Simulated Driving Study in Restless Legs Syndrome","status":"COMPLETED","sponsor":"XenoPort, Inc.","startDate":"2007-04","conditions":"Restless Legs Syndrome","enrollment":130},{"nctId":"NCT00617461","phase":"PHASE2","title":"A Clinical Study in Subjects With Neuropathic Pain From PHN Who Have Had an Inadequate Response to Gabapentin Treatment","status":"COMPLETED","sponsor":"XenoPort, Inc.","startDate":"2008-03","conditions":"Neuralgia, Postherpetic","enrollment":96},{"nctId":"NCT00333359","phase":"PHASE3","title":"XP13512 (Gabapentin Enacarbil) Extension Study in Patients With Restless Legs Syndrome.","status":"COMPLETED","sponsor":"XenoPort, Inc.","startDate":"2006-06","conditions":"Restless Legs Syndrome","enrollment":581},{"nctId":"NCT01332305","phase":"PHASE2","title":"Dose-Response and Pharmacokinetics of Gabapentin Enacarbil (GEn [XP13512 / GSK1838262]) in Restless Legs Syndrome","status":"COMPLETED","sponsor":"XenoPort, Inc.","startDate":"2007-01","conditions":"Restless Legs Syndrome","enrollment":217},{"nctId":"NCT00619476","phase":"PHASE2","title":"A Study In Patients With Neuropathic Pain From Post-Herpetic Neuralgia (PHN)","status":"COMPLETED","sponsor":"XenoPort, Inc.","startDate":"2008-02","conditions":"Neuralgia, Postherpetic","enrollment":376},{"nctId":"NCT00643760","phase":"PHASE2","title":"A Study In Patients With Neuropathic Pain From Diabetic Peripheral Neuropathy (DPN)","status":"COMPLETED","sponsor":"XenoPort, Inc.","startDate":"2008-03","conditions":"Neuropathy, Diabetic","enrollment":421},{"nctId":"NCT00311363","phase":"PHASE3","title":"Long-Term Study of Gabapentin Enacarbil (GEn, XP13512) vs. Placebo in Patients With Restless Legs Syndrome.","status":"COMPLETED","sponsor":"XenoPort, Inc.","startDate":"2006-04","conditions":"Restless Legs Syndrome","enrollment":327},{"nctId":"NCT01476124","phase":"PHASE1","title":"Drug Drug Interaction Study With Gabapentin Enacarbil and Morphine","status":"COMPLETED","sponsor":"XenoPort, Inc.","startDate":"2011-08","conditions":"Restless Legs Syndrome","enrollment":18}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Gabapentin Enacabil","XP13512","Gabapentin Enacarbil"],"phase":"phase_3","status":"active","brandName":"GEn (XP13512)","genericName":"GEn (XP13512)","companyName":"XenoPort, Inc.","companyId":"xenoport-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"XP13512 is a prodrug of gabapentin that uses a novel amino acid transporter-mediated delivery system to enhance absorption and bioavailability in the gastrointestinal tract. Used for Postherpetic neuralgia, Diabetic peripheral neuropathy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}